SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that produces acute, unpredictable relapses causing cumulative neurological disability. Satralizumab, a humanized, monoclonal recycling antibody that targets the interleukin-6 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Jeffrey L., Fujihara, Kazuo, Kim, Ho Jin, Marignier, Romain, O'Connor, Kevin C., Sergott, Robert C., Traboulsee, Anthony, Wiendl, Heinz, Wuerfel, Jens, Zamvil, Scott S., Anania, Veronica G., Buffels, Regine, Künzel, Thomas, Lekkerkerker, Annemarie N., Lennon-Chrimes, Siân, Pittock, Sean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982113/
https://www.ncbi.nlm.nih.gov/pubmed/36873431
http://dx.doi.org/10.3389/fneur.2023.1114667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982113/
https://www.ncbi.nlm.nih.gov/pubmed/36873431
http://dx.doi.org/10.3389/fneur.2023.1114667

Ejemplares similares